NTII: Neurobiological Technologies Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NTII: Neurobiological Technologies

NTII 0.0001000

0.0%

Dec 26 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Dr. John M. de Castro who wrote (29)	9/21/1997 12:19:00 AM
From: Cacaito	of 36

Probably the type two trial of Dynorphin was neccesary to increase is trading and/or deal value, at least it is at a more advance in the approval process so it is worth more. I did wonder why not procceding faster with it since its efficacy seems easy to prove if compared to the other two drugs. Xerecept and dodecanol from Pharmos are the contenders for the brain edema market, they probably could be synergistic, if they work. Bradycor (bradikinins inhibitors or blocckers) type two trials recently fail to show any efficacy, this is a tough field to succeed. Memantine, I hope they concentrate first in the neuropathic pain area, and once approved it will be easier in the dementia field.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next